Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homochlorcyclizine SCHEMBL1977999 | 0.98 | SMN1; SMN2 (1.00) | DRD3KCNH2CHRM2ADRA2ACYP2D6 | |
| Homochlorcyclizine SCHEMBL122573 | 0.98 | SMN1; SMN2 (1.00) | DRD3KCNH2CHRM2ADRA2ACYP2D6 | |
| Chlorcyclizine SCHEMBL16769331 | 0.94 | KCNH2 (1.00) | DRD3KCNH2CHRM2ADRA2ACYP2D6 | |
| Chlorcyclizine SCHEMBL12157065 | 0.94 | KCNH2 (1.00) | DRD3KCNH2CHRM2ADRA2ACYP2D6 | |
| Chlorcyclizine SCHEMBL13724147 | 0.94 | KCNH2 (1.00) | DRD3KCNH2CHRM2ADRA2ACYP2D6 | |
| Chlorcyclizine SCHEMBL4383 | 0.94 | KCNH2 (1.00) | DRD3KCNH2CHRM2ADRA2ACYP2D6 | |
| Chlorcyclizine SCHEMBL321657 | 0.92 | CYP2D6 (1.00) | DRD3KCNH2CHRM2ADRA2ACYP2D6 | |
| SCHEMBL2056217 | 0.87 | CHRM2 (0.86) | DRD3KCNH2CHRM2ADRA2ACYP2D6 | |
| SCHEMBL7668121 | 0.85 | CHRM2 (0.83) | DRD3KCNH2CHRM2ADRA2ACYP2D6 | |
| SCHEMBL13309488 | 0.84 | CYP2D6 (0.71) | DRD3KCNH2CHRM2ADRA2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 636 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667707-B2 | SPNS2 neutralizing antibody | TEIJIN PHARMA LIMITED (JP) | 2023-06-06 | — | — | US | claimed |
| US-20220073444-A1 | Compounds, Compositions, and Methods for use in Treating Autophagy-Associated Disorders | BIOPHAGY INC (US) | 2022-03-10 | — | — | US | claimed |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BIOPHAGY INC (US) | 2021-12-28 | — | — | US | claimed |
| US-20210147523-A1 | SPNS2 NEUTRALIZING ANTIBODY | TEIJIN PHARMA LIMITED (JP) | 2021-05-20 | — | — | US | claimed |
| EP-3778631-A1 | SPNS2 NEUTRALIZING ANTIBODY | Teijin Pharma Limited (JP) | 2021-02-17 | — | — | EP | claimed |
| US-10736910-B2 | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits | STC.UNM (US) | 2020-08-11 | — | — | US | claimed |
| WO-2020131924-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | Biophagy, Inc. (US) | 2020-06-25 | — | — | WO | claimed |
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BIOPHAGY INC (US) | 2020-06-18 | — | — | US | claimed |
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | UNM RAINFOREST INNOVATIONS | 2020-03-10 | — | — | US | claimed |
| US-20190269806-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | UNM RAINFOREST INNOVATIONS | 2019-09-05 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1861003-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | Mentis Cura ehf. (IS) | 2007-12-05 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070123517-A1 | Pharmacological treatment for sleep apnea | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-05-31 | — | — | US | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006094797-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | MENTIS CURA EHF. (IS) | 2006-09-14 | — | — | WO | claimed |
| WO-2005094832-A1 | COMPOSITIONS COMPRISING MELOXICAM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | WO | claimed |
| EP-1572202-A2 | USE OF SEROTONIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2004041272-A2 | USE OF SEROTONIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2004-05-21 | — | — | WO | claimed |
| US-20030130266-A1 | Pharmacological treatment for sleep apnea | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2003-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BECN1, ATG7, SQSTM1 | DRD3 4416/4885KCNH2 4822/4885CHRM2 3916/4885 |
| US-20190269806-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | BECN1, RABGGTB, TFEB | DRD3 55/4885KCNH2 3752/4885CHRM2 546/4885 |
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | BECN1, TFEB, ATG7 | DRD3 349/4885KCNH2 3939/4885CHRM2 1723/4885 |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BECN1, ATG7, SQSTM1 | DRD3 4416/4885KCNH2 4822/4885CHRM2 3916/4885 |
| US-20220073444-A1 | Compounds, Compositions, and Methods for use in Treating Autophagy-Associated Disorders | BECN1, ATG7, SQSTM1 | DRD3 4416/4885KCNH2 4822/4885CHRM2 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.